Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

NCT07784959 is registered in ClinicalTrials.gov with Nuvectis Pharma, Inc. as lead sponsor.

NCT NCT07784959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07784959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer
Lead sponsor
Nuvectis Pharma, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 17, 2026
Completion date
February 29, 2028
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk positive, alk positive non-small cell lung cancer, alk+ non-small-cell lung carcinoma, nsclc